20021117
LAST month, the Food and Drug Administration approved a new cholesterol-lowering drug called Zetia. Developed jointly by Merck and Schering-Plough, it should be in drugstores by the end of this month. Another drug that lowers cholesterol, called Crestor, is under development by AstraZeneca and is expected to be approved next year.  There certainly seems to be a market for these drugs: the National Institutes of Health came out with new guidelines last year for treatment of high cholesterol, which are expected to nearly triple the number of people who might need drug therapy to get their cholesterol levels under control, to 36 million from 13 million.  To see the full article, subscribe here. 
